MedTrace Logo

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

NCT04999592 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-04-17

Study results available
· View outcomes & findings →

Summary

Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.

Conditions

Interventions

DRUG

Standard of care without prophylaxis

Administer antibiotics in response to infection

DRUG

Antibiotic prophylaxis

Ceftriaxone 2 gm IV q12h for 3 days

Sponsors & Collaborators

  • MaineHealth

    collaborator OTHER

  • National Institute of General Medical Sciences (NIGMS)

    collaborator NIH

  • University of New England

    collaborator OTHER

  • David J. Gagnon

    lead OTHER

Principal Investigators

  • David Gagnon, PharmD · MaineHealth

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-20
Primary Completion
2024-03-01
Completion
2024-11-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999592 on ClinicalTrials.gov